Unchained Labs, a life sciences tool startup backed by pharmaceutical company Novo, has raised $25m in series B funding, according to a securities filing on Wednesday.
Founded in 2015, Unchained has developed a range of tools for biologics research, including a biologics stability screener, an aggregation predictor and a protein sizing system.
Unchained previously raised $25m in a February 2015 series A round led by Novo Ventures, a corporate venturing subsidiary of Novo. The round also featured venture capital firm Canaan Partners and TPG Biotech, the life sciences subsidiary of investment form TPG.
The funding comes three weeks after Unchained bought biopharmaceutical automation technology developer Freeslate for an undisclosed amount. The acquisition is its fourth in just over a year.